Corpus Cavernosum from Men with Vasculogenic Impotence Is Partially Resistant to Adenosine Relaxation due to Endothelial A_2BReceptor Dysfunction

2001, Pharmacol Rev, 53, 417

10.1038/sj.bjp.0704675

10.1016/S0022-5347(01)62299-7

1992, J Urol, 147, 220, 10.1016/S0022-5347(17)37201-4

2003, Am J Physiol, 284, R682

2002, Br J Pharmacol, 136, 696

1994, Br J Clin Pharmacol, 38, 357, 10.1111/j.1365-2125.1994.tb04366.x

10.1016/S0022-5347(01)66311-0

10.1021/jm00345a001

2005, Am J Physiol, 288, H2439

10.1038/sj.bjp.0705697

10.1111/j.1474-1644.2005.03231_10.x

10.1046/j.1365-2605.2000.00232.x

2001, Pharmacol Rev, 53, 527

1999, Mol Urol, 3, 51

10.1006/bbrc.1994.1314

10.1016/0262-1746(86)90188-5

10.1038/sj.bjp.0702462

1994, Int J Impot Res, 6, 191

10.1021/jm990421v

2000, Naunyn-Schmiedeberg's Arch Pharmacol, 362, 383

10.1006/jsre.1998.5439

1999, Mol Pharmacol, 56, 705

2003, J Physiol (Lond), 549.2, 399

1995, J Androl, 16, 312, 10.1002/j.1939-4640.1995.tb00535.x

1989, J Fam Pract, 29, 210

10.1016/S0014-2999(01)01167-0

10.1111/j.1476-5381.1995.tb15923.x

2003, Am J Cardiol, 92, 9M

1990, Naunyn-Schmiedeberg's Arch Pharmacol, 341, 388

10.1042/cs0920269

10.1111/j.1469-7793.1997.135bf.x

10.1016/S0163-7258(01)00152-8

1992, Int J Impot Res, 4, 27

10.1001/jama.294.23.2996

1992, Pharmacology, 45, 241, 10.1159/000139007

10.1093/molehr/2.2.105

10.1007/s002100000309